Narrative updates are currently in beta.

Back to narrative

Digital Platforms And AI Will Reshape Future Healthcare

AMWL logo
AMWL
AnalystConsensusTarget
Not Invested
Published 04 Apr 2025

Update shared on08 Aug 2025

Previous
AnalystConsensusTarget's Fair Value
US$9.50
24.7% undervalued intrinsic discount
15 Aug
US$7.15
Loading
1Y
-17.4%
7D
-1.8%

American Well’s valuation has weakened as its Future P/E increased and Net Profit Margin declined, justifying a stagnant analyst price target at $9.50.


What's in the News


  • Amwell, as part of a Leidos-led partnership, was awarded an extension of its Digital First contract to support the Military Health System (MHS), serving about 9.6 million beneficiaries.
  • The Amwell technology-enabled care platform has been successfully deployed across the global Department of Defense enterprise, MEPCOM, and the U.S. Coast Guard, replacing the prior MHS Video Connect solution.
  • The platform is fully integrated with the MHS electronic health record and supports dynamic health solutions for military care teams and beneficiaries.
  • Amwell's solutions enhance efficiency, reduce care team burdens, improve beneficiary health, lower costs, and optimize the use of Defense Health Agency clinical resources globally.

Valuation Changes


Summary of Valuation Changes for American Well

  • The Consensus Analyst Price Target remained effectively unchanged, at $9.50.
  • The Future P/E for American Well has significantly risen from 6.90x to 9.24x.
  • The Net Profit Margin for American Well has significantly fallen from 11.52% to 8.63%.

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.